Carlsmed
Company Overview
Carlsmed is dedicated to transforming spine surgery through personalized solutions. Their mission is to improve outcomes and reduce healthcare costs for spine surgery and related areas. The company's aprevoae personalized surgery platform is designed to elevate the standard of care for spine surgery on an individual patient basis.
Core Values and Leadership
Carlsmed operates on three core principles: patient obsession, integrity, and teamwork. The leadership team is composed of experienced professionals including CEO Mike Cordonnier, CFO Leo Greenstein, Chief Legal Officer Jennifer Kamocsay, and other senior executives specializing in clinical, commercial, technology, and regulatory domains.
Achievements and Timeline
Carlsmed is the first company to receive FDA Breakthrough Device Designation for Intervertebral Spine Fusion Technology. They have received multiple FDA clearances and CMS reimbursement approvals since 2020. The company went public on Nasdaq in 2025 and continues to advance spinal fusion surgery technology and personalized procedural solutions.